A
Axon Therapies
Rebalancing Heart Failure | Axon Therapies
About Axon Therapies
Axon Therapies operates in the medical device industry, focusing on innovative solutions for heart failure management. The company has developed a novel catheter system that leverages splanchnic ablation for volume management (SAVM). This system aims to treat a root cause of heart failure by selectively ablating a nerve pathway to restore volume balance, halt disease progression, and improve patient symptoms. Axon Therapies primarily serves healthcare providers and cardiologists who treat patients with heart failure. The company's business model involves the development and eventual commercialization of its investigational device, which is currently not approved for clinical use in any geography. Revenue will be generated through the sale of the Ablation System once it receives regulatory approval.
Source: Dealroom company dataNews
Open roles
Funding history
Company financing events and reported valuations.
| Deal type | Date | Amount | Valuation | Investors | Source |
|---|---|---|---|---|---|
| SERIES A✓Equity / VC | Sep 2025 | $32M | $128M | Deerfield · Earlybird Venture Capital · CD Capital · KOFA Healthcare Investments | ↗ |
| OtherOther financing | Jul 2019 | $0 | — | Deerfield · Action Potential Venture Capital | — |
Growth signals
Latest recorded traffic for Axon Therapies is 900 monthly website visits, down 25% over the last three months. Axon Therapies's team grew 11.1% over the past year.
Similar companies
Company identity and context are open; selected comparison metrics preview what is available on the platform.
Investments and acquisitions
Recent portfolio relationships for companies that also act as investors or acquirers.
Axon Therapies in the Santa Clara ecosystem
The Axon Therapies office with the hot startups, most funded companies and investors around it. Hover or tap a pin.
Dealroom maps whole ecosystems like this one for cities, regions and governments. See the ecosystem platform →
Investors
From Dealroom's funding and investor records, grouped by the round each investor first entered.
Series A5 investors entered at this stage
Earlybird Venture Capital
Sante Ventures
Deerfield
CD Capital- KIKOFA Healthcare Investments
Other known investors1 additional known investor
Action Potential Venture Capital
Source: Dealroom Talent Intelligence.
Global footprint
team presence
Market sentiment
An AI-synthesised read of the highest-engagement posts about Axon Therapies on X, ranked by likes and reposts, corporate channels excluded.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See Axon Therapies’s full profile on Dealroom
Request a free trial to see the complete deal history, financials, people graph and growth signals.
Takes under a minute. Already use Dealroom? Log in.








